Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-Environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Southwest University, Chongqing, China.
Shanghai Clinic and Research Center of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai Key Laboratory of Tuberculosis, Shanghai, China.
Microbiol Spectr. 2022 Dec 21;10(6):e0209822. doi: 10.1128/spectrum.02098-22. Epub 2022 Dec 1.
Tuberculosis (TB) caused by Mycobacterium tuberculosis infection remains one of the most serious global health problems. Fluoroquinolones (FQs) are an important component of drug regimens against multidrug-resistant , but challenged by the emergence of FQ-resistant strains. Mycobacterium fluoroquinolone resistance protein A (MfpA) is a pentapeptide protein that confers resistance to FQs. MfpA is the fifth gene in the operon among most Mycobacterium, implying other genes might regulate the activity of MfpA. To elucidate the function of this operon, we constructed deletion mutants and rescued strains and found that MfpD is a GTPase-activating protein (GAP) involved in FQs activity. We showed that the recombinant strains overexpressing became more sensitive to FQs, whereas an deletion mutant was more resistant to FQs. By using site-directed mutagenesis and mycobacterial protein fragment complementation, we genetically demonstrated that participated in FQs susceptibility via directly acting on . We further biochemically demonstrated that MfpD was a GAP capable of stimulating the GTPase activity of MfpB. Our studies suggest that MfpD, a GAP of MfpB, is involved in MfpA-mediated FQs resistance. The function of MfpD adds new insights into the role of the operon in Mycobacterium fluoroquinolone resistance. Tuberculosis is one of the leading causes of morbidity and mortality worldwide largely due to increasingly prevalent drug-resistant strains. Fluoroquinolones are important antibiotics used for treating multidrug-resistant tuberculosis (MDR-TB). The resistance mechanism mediated by the Mycobacterium fluoroquinolone resistance protein (MfpA) is unique in Mycobacterium. However, the regulatory mechanism of MfpA remains largely unclear. In this study, we first report that MfpD acts as a GAP for MfpB and characterize a novel pathway that controls Mycobacterium small G proteins. Our findings provide new insights into the regulation of MfpA and inspiration for new candidate targets for the discovery and development of anti-TB drugs.
结核病(TB)是由结核分枝杆菌感染引起的,仍然是全球最严重的健康问题之一。氟喹诺酮类(FQs)是治疗耐多药结核病的药物方案的重要组成部分,但面临着 FQ 耐药菌株的出现。结核分枝杆菌氟喹诺酮耐药蛋白 A(MfpA)是一种五肽蛋白,赋予 FQ 耐药性。MfpA 是大多数分枝杆菌 操纵子中的第五个基因,这意味着其他 基因可能调节 MfpA 的活性。为了阐明该操纵子的功能,我们构建了缺失突变体和拯救菌株,并发现 MfpD 是一种参与 FQ 活性的 GTPase 激活蛋白(GAP)。我们表明,过表达 的重组菌株对 FQ 更加敏感,而 缺失突变体对 FQ 更具抗性。通过使用定点突变和分枝杆菌蛋白片段互补,我们从遗传学上证明 通过直接作用于 参与 FQ 易感性。我们进一步通过生化实验证明,MfpD 是一种 GAP,能够刺激 MfpB 的 GTPase 活性。我们的研究表明,MfpD 作为 MfpB 的 GAP,参与了 MfpA 介导的 FQ 耐药性。MfpD 的功能为 操纵子在结核分枝杆菌氟喹诺酮耐药性中的作用提供了新的见解。结核病是全球发病率和死亡率的主要原因之一,主要是由于日益流行的耐药菌株。氟喹诺酮类是用于治疗耐多药结核病(MDR-TB)的重要抗生素。由结核分枝杆菌氟喹诺酮耐药蛋白(MfpA)介导的耐药机制在分枝杆菌中是独特的。然而,MfpA 的调节机制在很大程度上仍不清楚。在这项研究中,我们首次报道 MfpD 作为 MfpB 的 GAP 发挥作用,并描述了一种控制分枝杆菌小 G 蛋白的新途径。我们的发现为 MfpA 的调控提供了新的见解,并为发现和开发抗结核病药物的新候选靶点提供了启示。